Lophora
@lophora.com
Lophora is a clinical-stage CNS company developing neuroactive medicines for depression, anxiety, eating disorders, PTSD and substance use disorders.
Lophora's Company Logos
Lophora's Brand Colors
Hex Code
Color name
RGB
HSL
CMYK
#EEC574
Rob Roy
238, 197, 116
40, 78, 69
0, 17, 51, 7
#FFFFFF
White
255, 255, 255
0, 0, 100
0, 0, 0, 0
#286354
Casal
40, 99, 84
165, 42, 27
60, 0, 15, 61
About Lophora
Lophora is a groundbreaking drug development start-up focused on providing relief for individuals suffering from treatment-resistant depression and other central nervous system (CNS) diseases. Founded in 2018, Lophora has made significant progress in the characterization of its lead-candidate drug, thanks to funding from the BioInnovation Institute. By 2023, Lophora plans to initiate the first-in-human trials for its innovative rapid-acting drugs.
What sets Lophora apart is its discovery and patenting of a new class of proprietary ligands that possess a pharmacological profile similar to psilocybin. Psilocybin has demonstrated promising clinical results in treating depression. While Lophora is currently focusing on Treatment-Resistant Depression, their research suggests that this new drug class shows potential in addressing other CNS disorders such as anxiety, PTSD, and substance abuse.
With their pre-clinical operations well underway and expected IND status by the end of Q1 2023, Lophora holds a unique position in the market for future anti-depressant therapies. Their expertise and pioneering technology position them at the forefront of the global shift towards Psychedelic-assisted therapy for CNS disorders. To learn more about Lophora and their novel treatment paradigm, you can get in touch with them at bt@lophora.
com or by calling +45 51 86 84 82. Lophora is headquartered at the BioInnovation Institute at COBIS Science Park in Copenhagen, Denmark. Copyright © 2023 Lophora
Company type
Privately Held
Year founded
2018
Company size
2-10 employees
